{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-049260","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.946568+00:00","generated_at":"2026-06-05T08:58:12.504182+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"vTv Therapeutics closes $51M private placement to fund Phase 3 study of cadisegliatin","bullets":["Closed $51M private placement with institutional investors (Samsara BioCapital, JDRF T1D Fund) at $11.81/share (45-day VWAP).","Issued 464,377 shares and pre-funded warrants for 3,853,997 shares at $0.01 exercise price.","Proceeds to fully fund first Phase 3 study of cadisegliatin (TTP399) for type 1 diabetes, expected to start mid-2024.","Board reduced from 9 to 7 members; lead investors to designate three directors; Srinivas Akkaraju (Samsara) appointed.","CEO Paul Sekhri's salary increased to $650,000 from $480,000; granted option for 89,212 shares at $11.81."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-049260","json":"https://secwatch.observer/filing/0001193125-24-049260.json","markdown":"https://secwatch.observer/filing/0001193125-24-049260.md","text":"https://secwatch.observer/filing/0001193125-24-049260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/d754681d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:58:12.504182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17fcd041b9","claim":"Srinivas Akkaraju was elected as Director at vTv Therapeutics Inc..","evidence_excerpt":"Raymond Cheong and Srinivas Akkaraju were each elected as directors of the Company, effective and contingent on the closing of the Private Placement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1a84c355c0","claim":"Keith Harris resigned as Director at vTv Therapeutics Inc..","evidence_excerpt":"Keith Harris agreed to resign as a member of the Board and the Audit Committee of the Board, effective following the later of (a) the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and (b) the appointment of a director pursuant to Section 7.9(c) of the Securities Purchase Agreement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"548956f683","claim":"Jonathan Isaacsohn resigned as Director at vTv Therapeutics Inc..","evidence_excerpt":"Jonathan Isaacsohn resigned as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"74d85c9aa6","claim":"Hersh Kozlov resigned as Director at vTv Therapeutics Inc..","evidence_excerpt":"Hersh Kozlov resigned as a member of the Board, the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective and contingent on the closing of the Private Placement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b3b8dc9dac","claim":"John A. Fry resigned as Director at vTv Therapeutics Inc..","evidence_excerpt":"John A. Fry agreed to resign as a member of the Board, the Audit Committee and Nominating and Corporate Governance Committee of the Board and Howard L. Weiner agreed to resign as a member of the Board and the Audit Committee of the Board, effective as of the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f73a3d5608","claim":"Howard L. Weiner resigned as Director at vTv Therapeutics Inc..","evidence_excerpt":"Howard L. Weiner agreed to resign as a member of the Board and the Audit Committee of the Board, effective as of the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fb9c1c4098","claim":"Raymond Cheong was elected as Director at vTv Therapeutics Inc..","evidence_excerpt":"Raymond Cheong and Srinivas Akkaraju were each elected as directors of the Company, effective and contingent on the closing of the Private Placement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6b804184c9c857c3b4a43210a38916dd1dac1972","claim":"vTv Therapeutics Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Warrant Shares held by the Purchasers","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the Purchasers"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"},{"claim_id":"cf8ddf8d08c43a493773f3cd1cebf68cb4110391","claim":"vTv Therapeutics Inc. amended G42 Amendment with G42 Investments AI Holdings RSC Ltd (effective 2024-02-27).","evidence_excerpt":"the Company entered into an amendment to the Common Stock Purchase Agreement with G42 Investments AI Holdings RSC Ltd (“G42”) (the “G42 Amendment”), on February 27, 2024","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"G42 Investments AI Holdings RSC Ltd"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"},{"claim_id":"f3a22e69e2e6006e9c5dbab6b2b957abfd0b2d2f","claim":"vTv Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at aggregate gross proceeds of approximately $51.0 million (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, vTv Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Shares”) of the Company’s Class A common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 3,853,997 shares of Common Stock (the “Warrant Shares”) at a purchase price of $11.80 per Pre-Funded Warrant","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"aggregate gross proceeds of approximately $51.0 million"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}